Can a Two-Drug punch restore sensitivity in Hard-to-Treat prostate cancer?
NCT ID NCT05037500
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether adding decitabine/cedazuridine to enzalutamide could help men with metastatic castration-resistant prostate cancer whose cancer had stopped responding to enzalutamide alone. Only 8 men were enrolled before the study was terminated. The goal was to find a safe dose and see if the combination could reverse drug resistance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine and cedazuridine (ASTX727, Inqovi) combined with enzalutamide (Xtandi)
What this could lead to
If it works, this combination could help men with advanced prostate cancer whose disease has stopped responding to enzalutamide alone.
What could go wrong
This was a very early, small Phase 1b trial that was terminated, so results are limited. The combination may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States